Mitsui Chemicals has signed an agreement to acquire JSR Corp. from investment funds managed by JIC Capital, a move that would make the Tokyo-based semiconductor-materials maker a consolidated subsidiary. The transaction is valued at ¥1.84 trillion ($11.6 billion) including debt. Mitsui breaks the consideration into equity value of ¥1.3921 trillion ($8.8 billion) and ¥447.9 billion ($2.8 billion) of interest-bearing debt and other items, with the final amount subject to adjustment at closing.
The share purchase is being made jointly with Development Bank of Japan (DBJ), which will invest ¥200 billion ($1.3 billion). Mitsui will buy all JSR common shares held by JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership. It also expects to acquire JSR’s Class A and Class B preferred shares from Mizuho Bank and DBJ for cash. Those preferred shares are slated to convert to common shares after closing, while DBJ’s common shares will be converted to non-voting preferred shares. The structure brings in DBJ as an investor while limiting its voting position through the conversion feature.
Mitsui presents the acquisition as supporting its VISION 2030 plan, which combines a specialty-chemicals pillar—Life & Healthcare Solutions, Mobility Solutions and ICT Solutions—with a Basic & Green Materials pillar centered on petrochemicals. JSR’s advanced photoresists, customer base in semiconductors and optics, and global reach are described as making it core to the ICT Solutions domain. The intended industrial fit is specific: Mitsui plans to combine its MITSUI PELLICLE products and JSR’s advanced photoresists in front-end processes, and its ICROS Tape and thick-film resists in back-end processes. Mitsui targets about ¥40 billion ($253 million) of annual incremental profit by fiscal 2035 from growth and cost synergies, a goal rather than a current contribution.
JSR’s scale is meaningful. For the fiscal year ended March 2026, it reported revenue of ¥440.7 billion ($2.8 billion), consolidated operating profit of ¥40.5 billion ($256 million) and profit attributable to owners of ¥59.3 billion ($375 million). Those figures describe the business being acquired, but the transaction’s final economics will also reflect debt, preferred-share treatment and closing adjustments.
The financing plan is designed to absorb a large purchase before equity and refinancing catch up. Funding is expected to come from a ¥1.64 trillion ($10.4 billion) bridge loan from Mitsui’s principal financial institutions and DBJ’s ¥200 billion investment. Mitsui expects net debt/EBITDA to temporarily exceed 4x after closing. To protect an “A”-category credit rating, it plans to refinance the bridge loan within one year of closing through bank loans, bonds and equity. It aims to have the equivalent of ¥300 billion ($1.9 billion) recognized as equity by rating agencies, cap common share issuance including treasury shares at ¥150 billion ($948 million), and add ¥300 billion of mezzanine financing, of which 50% is assumed to count as equity.
A shelf registration filed on Nov. 9 covers up to ¥150 billion of common shares. It becomes effective Nov. 17, 2026, and runs through Nov. 16, 2028, with proceeds intended for partial repayment of the bridge loan. SMBC Nikko Securities and Mizuho Securities are expected to be primary underwriters. The combination of a bridge facility, a capped equity issuance and mezzanine capital shows that the deal’s balance-sheet mechanics are as important as the industrial rationale: the company is trying to preserve rating-agency equity credit while still funding the acquisition.
Mitsui is also reshaping the rest of its portfolio. It first said in May 2025 that it would consider splitting off its Basic & Green Materials business. It now plans to add Mobility Solutions to the scope, aiming to form a polymer science company with an integrated polymer chain spanning upstream petrochemicals and downstream functional polymers. The company also plans to become more asset-light in underperforming businesses, improve its cash conversion cycle and sell shareholdings. Alongside JSR’s review of its life-sciences business—contract research and contract development and manufacturing, which JSR treats as non-core—Mitsui expects benefits representing business value of ¥350 billion ($2.2 billion) or more.
The acquired perimeter extends beyond photoresists. Four JSR affiliates will become specified subsidiaries of Mitsui: Inpria Corp. in Corvallis, Oregon; KBI Biopharma in Durham, North Carolina; JSR North America Holdings in Sunnyvale, California; and JSR Life Sciences in Sunnyvale. The list includes life-sciences and North American entities, so integration will involve governance and portfolio decisions beyond the front-end and back-end semiconductor materials that anchor the strategic case.
Completion is not immediate. The transaction is subject to competition-law and foreign-investment approvals in Japan and overseas. Mitsui is aiming to close in the second half of the fiscal year ending March 2028 and expects the impact on results for the fiscal year ending March 2027 to be minor. Those conditions bound the near-term effect: until approvals are obtained and the deal closes, JSR is not part of Mitsui’s consolidated results, and the targeted synergies remain forward-looking.
The strategic logic is to pair Mitsui’s existing semiconductor-process materials with JSR’s photoresist portfolio and customer access, while pointing to JSR’s life-sciences review and Mitsui’s own portfolio actions as additional sources of value. The main tension is financial. A purchase that temporarily pushes leverage above 4x requires the bridge loan to be replaced within a year, depends in part on rating agencies granting substantial equity credit, and keeps equity issuance within the ¥150 billion cap. The ¥40 billion annual profit target by fiscal 2035 is also distant enough that integration and market conditions will determine whether the combination delivers the intended growth and cost benefits.
If completed, the transaction would make Mitsui a larger presence in semiconductor materials and test its ability to integrate a broad acquired perimeter without weakening the credit profile it is trying to protect. The approvals, the refinancing and the delivery of synergies are the key checkpoints between the signed agreement and the strategic result Mitsui is targeting.